Associations of mucinous differentiation and mucin expression with immune cell infiltration and prognosis in colorectal adenocarcinoma
Elomaa, Hanna; Tarkiainen, Vilma; Äijälä, Ville K.; Sirniö, Päivi; Ahtiainen, Maarit; Sirkiä, Onni; Karjalainen, Henna; Kastinen, Meeri; Tapiainen, Vilja V.; Rintala, Jukka; Meriläinen, Sanna; Saarnio, Juha; Rautio, Tero; Tuomisto, Anne; Helminen, Olli; Wirta, Erkki-Ville; Seppälä, Toni T.; Böhm, Jan; Mäkinen, Markus J.; Mecklin, Jukka-Pekka; Väyrynen, Juha P. (2025-02-18)
Elomaa, Hanna
Tarkiainen, Vilma
Äijälä, Ville K.
Sirniö, Päivi
Ahtiainen, Maarit
Sirkiä, Onni
Karjalainen, Henna
Kastinen, Meeri
Tapiainen, Vilja V.
Rintala, Jukka
Meriläinen, Sanna
Saarnio, Juha
Rautio, Tero
Tuomisto, Anne
Helminen, Olli
Wirta, Erkki-Ville
Seppälä, Toni T.
Böhm, Jan
Mäkinen, Markus J.
Mecklin, Jukka-Pekka
Väyrynen, Juha P.
Springer
18.02.2025
Elomaa, H., Tarkiainen, V., Äijälä, V.K. et al. Associations of mucinous differentiation and mucin expression with immune cell infiltration and prognosis in colorectal adenocarcinoma. Br J Cancer 132, 660–669 (2025). https://doi.org/10.1038/s41416-025-02960-3.
https://creativecommons.org/licenses/by/4.0/
© The Author(s) 2025. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
https://creativecommons.org/licenses/by/4.0/
© The Author(s) 2025. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
https://creativecommons.org/licenses/by/4.0/
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:oulu-202502201762
https://urn.fi/URN:NBN:fi:oulu-202502201762
Tiivistelmä
Abstract
Background:
The production of extracellular mucus and expression of mucins are commonly aberrant in colorectal cancer, yet their roles in tumour progression remain unclear.
Methods:
To investigate the potential influence of mucus on immune response and prognosis, we analysed mucinous differentiation (non-mucinous, 0%; mucinous component, 1–50%; mucinous, >50%) and its associations with immune cell densities (determined with three multiplex immunohistochemistry assays or conventional immunohistochemistry) and survival in 1049 colorectal cancer patients and a validation cohort of 771 patients. We also assessed expression patterns of transmembrane (MUC1, MUC4) and secreted (MUC2, MUC5AC and MUC6) mucins using immunohistochemistry.
Results:
Mucinous differentiation was associated with higher densities of CD14+HLADR– immature monocytic cells and M2-like macrophages in mismatch repair (MMR) proficient tumours, and lower T-cell densities in MMR-deficient tumours. Mucinous differentiation was not associated with cancer-specific survival in multivariable Cox regression models. Higher cytoplasmic MUC1 expression independently predicted worse cancer-specific survival (multivariable HR for high vs. negative to low expression, 2.14; 95% CI: 1.26–3.64). It was also associated with increased myeloid cell infiltration in MMR-proficient tumours.
Conclusions:
Although mucinous differentiation did not independently predict survival, extracellular mucus and MUC1 expression could promote tumour progression through immunosuppression.
Background:
The production of extracellular mucus and expression of mucins are commonly aberrant in colorectal cancer, yet their roles in tumour progression remain unclear.
Methods:
To investigate the potential influence of mucus on immune response and prognosis, we analysed mucinous differentiation (non-mucinous, 0%; mucinous component, 1–50%; mucinous, >50%) and its associations with immune cell densities (determined with three multiplex immunohistochemistry assays or conventional immunohistochemistry) and survival in 1049 colorectal cancer patients and a validation cohort of 771 patients. We also assessed expression patterns of transmembrane (MUC1, MUC4) and secreted (MUC2, MUC5AC and MUC6) mucins using immunohistochemistry.
Results:
Mucinous differentiation was associated with higher densities of CD14+HLADR– immature monocytic cells and M2-like macrophages in mismatch repair (MMR) proficient tumours, and lower T-cell densities in MMR-deficient tumours. Mucinous differentiation was not associated with cancer-specific survival in multivariable Cox regression models. Higher cytoplasmic MUC1 expression independently predicted worse cancer-specific survival (multivariable HR for high vs. negative to low expression, 2.14; 95% CI: 1.26–3.64). It was also associated with increased myeloid cell infiltration in MMR-proficient tumours.
Conclusions:
Although mucinous differentiation did not independently predict survival, extracellular mucus and MUC1 expression could promote tumour progression through immunosuppression.
Kokoelmat
- Avoin saatavuus [38865]